Stock listing

NASDAQ:LYCA Lycia Therapeutics, Inc. Stock

Home listing (NASDAQ) of Lycia Therapeutics, Inc.

Follow Lycia Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:LYCA

$33.07 USD +1.72 (+5.5%)

Close on Nov 20, 2026

Past month +10.2% · daily closes, Oct 23, 2026 – Nov 20, 2026, adjusted for splits
Day range
$31.01 – $34.59 USDNov 20, 2026
Volume
422,136 sharesNov 20, 2026
Market cap
$1.72B USDAt the close on Nov 20, 2026 · price × 52.09M shares outstanding
Traded on an average day
$13.05M USDMedian day 316,082 shares · last 3 months, Oct 23, 2026 – Nov 20, 2026

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:LYCA · Home$33.07 USD+1.72 (+5.5%)422,136$31.86$34.59$31.01$31.35Close on Nov 20, 2026

Daily closes

Last 3 months, Oct 23, 2026 – Nov 20, 2026 · NASDAQ:LYCA · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$33.07+1.72+5.5%$31.86$34.59$31.01422,136
$31.35+0.43+1.4%$30.45$32.85$30.45383,616
$30.92+2.31+8.1%$28.62$31.72$28.62496,158
$28.61-2.59-8.3%$31.23$32.40$28.18250,870
$31.20-1.63-5.0%$32.83$33.00$31.20189,539
$32.83+1.39+4.4%$32.00$33.44$30.90496,078
$31.44+0.14+0.4%$31.50$33.56$31.01329,514
$31.30+0.94+3.1%$30.36$31.57$29.88239,518
$30.36-0.14-0.5%$30.35$30.68$28.77184,429
$30.50+1.70+5.9%$28.91$31.18$28.91369,987
$28.80-0.12-0.4%$29.16$29.34$27.94189,794
$28.92+1.32+4.8%$27.48$28.92$26.42302,649
$27.60+0.42+1.5%$26.98$28.03$26.98195,317
$27.18+0.78+3.0%$27.14$27.66$26.01270,514
$26.40-1.33-4.8%$27.17$27.59$25.66202,400
$27.73+2.68+10.7%$25.25$27.83$24.51173,100
$25.05-1.06-4.1%$26.48$26.48$24.03433,100
$26.11-2.74-9.5%$26.51$28.00$24.63426,800
$28.85-1.15-3.8%$23.73$30.91$23.73965,500
$30.00——$28.55$36.49$22.192,284,000
Ticker
NASDAQ:LYCA
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Lycia Therapeutics, Inc. news

Lycia Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
3 in the last 12 months · 3 in all · newest Nov 11, 2026 · oldest 2026

Where Lycia Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:LYCA · Home listing · This pageNASDAQUnited StatesUSD
BOATS:LYCABOATSUnited StatesUSD

Valuation

EV/sales 237× against a median of 60.2×: the highest of 7 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$1.60B USD
P/E
Loss
EV/sales
237×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
Not reported
Operating margin
−591.6%
Net margin
−540.9%
Debt to equity
Negative equity
Beta vs S&P 500
Under 6 months of closes

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Lycia Therapeutics, Inc. · NASDAQ:LYCAUS$1.72BUS$1.60Bn/a237×n/an/a−540.9%n/an/a
Vera Therapeutics, Inc. · NASDAQ:VERAUS$1.84BUS$1.53Bn/a149×n/a5.5×n/a0.2×1.13
Hemab Therapeutics Holdings, Inc. · NASDAQ:COAGUS$1.84BUS$1.41Bn/an/an/a4.3×n/a0.0×0.61
Braveheart Bio, Inc. · NASDAQ:BRVEUS$1.84BUS$1.71Bn/an/an/a3.7×n/a0.0×n/a
Septerna, Inc. · NASDAQ:SEPNUS$1.84BUS$1.38Bn/a14.3×n/a4.3×−61.3%0.1×0.95
Replimune Group, Inc. · NASDAQ:REPLUS$1.81BUS$1.60Bn/an/an/a8.8×n/a0.5×0.78
Neuren Pharmaceuticals Limited · ASX:NEUUS$1.76BUS$1.57B87.3×36.7×108×8.0×47.1%0.0×n/a
Stoke Therapeutics, Inc. · NASDAQ:STOKUS$1.75BUS$1.43Bn/a50.8×n/a5.0×−862.1%0.0×0.78
First Tracks Biotherapeutics, Inc. · NASDAQ:TRAXUS$1.75BUS$1.60Bn/an/an/a11.6×n/a0.0×1.80
Maze Therapeutics, Inc. · NASDAQ:MAZEUS$1.74BUS$1.39Bn/a69.6×n/a4.1×−757.4%0.1×0.66
Zenas BioPharma, Inc. · NASDAQ:ZBIOUS$1.62BUS$1.26Bn/a114×n/a7.6×n/a1.1×1.05
Median of the othersUS$1.78BUS$1.48B87.3×60.2×108×5.2×−409.3%0.0×0.87

Team and board

Officers

OfficerRole
Aetna Wun TrombleyPresident and CEO
Amy BachrodtChief Financial Officer
Winsome ChungSenior Vice President, Finance
Karen FlickGeneral Counsel
Darrin LindhoutVice President, Head of Biologics
Jian CaoVice President, Head of CMC
Lynne GeorgopoulosSenior Vice President, Regulatory Affairs and Clinical Operations
Nadia TchaoVice President, Head of Early Clinical Development
Naomi Arana-MiddendorfVice President, Program Management
Chin LeeChief Medical Officer
Sofia TouamiChief Business Officer
Steve StabenChief Scientific Officer

Board

DirectorRole
William J. RieflinChair, Lycia Therapeutics
Aetna Wun TrombleyPresident and CEO
Laurent FischerBoard Member

Financings

RaiseDate
Public offering of shares of common stock
Closed: US$365.1M raised · US$18 a share · Jefferies +4
Dealers: Jefferies (co-lead), TD Cowen (co-lead), Evercore ISI (co-lead), Guggenheim Securities (co-lead), LifeSci Capital
Oct 26, 2026
Public offering of common stock
Announced: about US$317.5M · US$18 a share · Jefferies +4
Dealers: Jefferies (co-lead), TD Cowen (co-lead), Evercore ISI (co-lead), Guggenheim Securities (co-lead), LifeSci Capital
Oct 22, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$18.00 a share on Oct 22, 2026.

Price
US$18.00 a share
Shares offered
17,640,000 shares of common stock
Offering size
US$317.5 million
Underwriters' option
Up to 2,646,000 more shares
Listing
LYCA on the Nasdaq Global Select Market
Underwriters
Jefferies, TD Cowen, Evercore ISI, Guggenheim Securities, LifeSci Capital · In the order on the cover
Shares delivered
On or about Oct 26, 2026

Steps

StepWhen
Draft sent to the SEC in confidenceJul 2, 2026
Filed publiclyOct 5, 2026
Amended onceOct 20, 2026
Shares registered with an exchangeOct 20, 2026
Declared effective by the SECOct 22, 2026
Final prospectus, with the priceOct 23, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Oct 23, 2026

Financials

Annual, in USD

Income statement

LineFY2025FY2024
Revenue6.74M14.9M
Research and development40.5M41.1M
Selling, general and administrative6.11M6.40M
Operating income-39.9M-32.5M
Depreciation and amortization1.19M1.18M
EBITDA-38.7M-31.4M
Interest expense31.0K39.0K
Income before tax-36.7M-26.5M
Net income-36.5M-26.5M

Balance sheet

LineFY2025FY2024
Cash and equivalents19.3M30.6M
Short-term investments59.9M107.4M
Current assets80.6M139.8M
Total assets97.2M150.9M
Accounts payable996.0K2.27M
Current liabilities6.49M23.3M
Total liabilities210.6M228.8M
Shareholders' equity-113.3M-77.9M

Cash flow

LineFY2025FY2024
Cash from operations-51.4M-29.5M
Capital spending-194.0K-1.27M
Free cash flow-51.6M-30.8M
Cash from financing77.0K106.4M
Share buybacks-3.00K0
Change in cash-11.3M17.2M

Open Financials

Filings

FilingDateTypeFiled with
4 · Change in ownershipNov 4, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeOct 30, 2026Big-stake noticeSEC
4 · Change in ownershipOct 30, 2026Insider tradeSEC
4 · Change in ownershipOct 28, 2026Insider tradeSEC
4 · Change in ownershipOct 27, 2026Insider tradeSEC
4 · Change in ownershipOct 26, 2026Insider tradeSEC
4 · Change in ownershipOct 26, 2026Insider tradeSEC
4 · Change in ownershipOct 26, 2026Insider tradeSEC
4 · Change in ownershipOct 26, 2026Insider tradeSEC
4 · Change in ownershipOct 26, 2026Insider tradeSEC
All 40 filings
FilingDateTypeFiled with
4 · Change in ownershipOct 26, 2026Insider tradeSEC
4 · Change in ownershipOct 26, 2026Insider tradeSEC
4 · Change in ownershipOct 26, 2026Insider tradeSEC
8-K · Current reportOct 26, 2026Current reportSEC
S-8 · Registration statement for employee plansOct 23, 2026Offer documentSEC
424B4 · ProspectusOct 23, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 23, 2026Other filingsSEC
3 · Initial statement of ownershipOct 22, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 22, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 22, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 22, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 22, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 22, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 22, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 22, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 22, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 22, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 22, 2026Insider tradeSEC
3 · Initial statement of ownershipOct 22, 2026Insider tradeSEC
S-1MEF · Registration of more shares for the same offeringOct 22, 2026Offer documentSEC
CERT · Exchange's certificate of listingOct 22, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeOct 20, 2026Other filingsSEC
S-1/A · Registration statement, amendedOct 20, 2026Offer documentSEC
S-1 · Registration statementOct 5, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedAug 27, 2026Offer documentSEC
DRS · Draft registration statementJul 2, 2026Offer documentSEC
DJun 25, 2026Other filingsSEC
DMay 23, 2024Other filingsSEC
DSep 15, 2021Other filingsSEC
DMar 17, 2020Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Lycia Therapeutics, Inc.’s releases · as of Oct 26, 2026

Common shares
52,094,559
Fully diluted
52,094,559

Fully diluted

LineSharesAs of
Common shares52,094,559Oct 26, 2026

Share count over time

CountShares
Oct 26, 202652,094,559

Open Cap table

Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Venrock Healthcare Capital Partners III, L.P.
10% owner
Buy8,305USD 26.95US$224KNov 2, 2026
Venrock Healthcare Capital Partners III, L.P.
10% owner
Buy8,804USD 26.27US$231KOct 30, 2026
Venrock Healthcare Capital Partners III, L.P.
10% owner
Buy200USD 26.86US$5,372Oct 30, 2026
Venrock Healthcare Capital Partners III, L.P.
10% owner
Buy1,000USD 26.33US$26,330Oct 29, 2026
Venrock Healthcare Capital Partners III, L.P.
10% owner
Buy10,570USD 25.23US$267KOct 28, 2026
Venrock Healthcare Capital Partners III, L.P.
10% owner
Buy4,430USD 25.97US$115KOct 28, 2026
Venrock Healthcare Capital Partners III, L.P.
10% owner
Buy8,729USD 25.84US$226KOct 27, 2026
Venrock Healthcare Capital Partners III, L.P.
10% owner
Buy31,067USD 26.84US$834KOct 27, 2026
Venrock Healthcare Capital Partners III, L.P.
10% owner
Buy1,944,444USD 18.00US$35MOct 26, 2026
Venrock Healthcare Capital Partners III, L.P.
10% owner
Buy8,261USD 26.97US$223KOct 26, 2026
All 12 trades
TradeTradeSharesPriceValueDate
Venrock Healthcare Capital Partners III, L.P.
10% owner
Buy24,560USD 25.68US$631KOct 23, 2026
Venrock Healthcare Capital Partners III, L.P.
10% owner
Buy28,379USD 26.11US$741KOct 23, 2026

Big stakes

StakeStakeSharesDateFiling
Venrock Healthcare Capital Partners III, L.P.11.90%6.85MOct 23, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Aetna Wun TrombleyPresident and CEO · Since at least Nov 5, 2026
Amy BachrodtChief Financial Officer · Since at least Nov 4, 2026
Chin LeeChief Medical Officer · Since at least Nov 4, 2026
Darrin LindhoutVice President, Head of Biologics · Since at least Nov 4, 2026
Jian CaoVice President, Head of CMC · Since at least Nov 4, 2026
Karen FlickGeneral Counsel · Since at least Nov 4, 2026
Laurent FischerBoard Member · Since at least Nov 5, 2026
Lynne GeorgopoulosSenior Vice President, Regulatory Affairs and Clinical Operations · Since at least Nov 4, 2026
Nadia TchaoVice President, Head of Early Clinical Development · Since at least Nov 4, 2026
Naomi Arana-MiddendorfVice President, Program Management · Since at least Nov 4, 2026
All 14 people
PersonSeat
Sofia TouamiChief Business Officer · Since at least Nov 4, 2026
Steve StabenChief Scientific Officer · Since at least Nov 4, 2026
William J. RieflinChair, Lycia Therapeutics · Since at least Nov 5, 2026
Winsome ChungSenior Vice President, Finance · Since at least Nov 4, 2026

Open People

Log in to ask 6ix AI your own questions about Lycia Therapeutics, Inc.